[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 3 days · First seen · Last updated

Braveheart Bio initial public offering

Overview

Braveheart Bio Inc., a biopharmaceutical company focused on therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, initiated its initial public offering on the Nasdaq Global Market. The company upsized its offering to 21,250,000 common shares priced at $18.00 per share, aiming to raise approximately $382.5 million in gross proceeds.

Following the completion of the $382 million IPO, company executives and directors engaged in significant insider stock purchases. These acquisitions included approximately $500,000 worth of shares by CFO James Paul Rickey and approximately $1 million worth of shares by director David Charles Lubner, both at the $18.00 per share price.

Entities

Nasdaq Global Market · David Charles Lubner · Securities and Exchange Commission · Goldman Sachs & Co. LLC · Braveheart Bio

Timeline

  1. 10 days ago

    [BUSINESS] 2 sources
    Braveheart Bio completes $382M IPO amid insider stock purchases

    Braveheart Bio completed a $382 million IPO for its heart disease drug candidate, while CFO and directors engaged in significant insider stock purchases.

  2. 12 days ago

    [BUSINESS] 2 sources
    Braveheart Bio Prices Upsized $18 IPO, Set to List on Nasdaq Aug. 6

    Braveheart Bio priced an upsized $18 IPO of 21.25 M shares, expecting $382.5 M proceeds, with trading on Nasdaq (BRVE) set for Aug 6, 2026.

Sources

marketwire.com · medcitynews.com · stocknews.com · stocktitan.net